Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study

Li-Ju Chen1,2‡, Fei-Yuan Hsiao1,2,3‡, Li-Juan Shen1,2,3, Fe-Lin Lin Wu1,2,3, Woei Tsay4, Chien-Ching Hung4, Shu-Wen Lin1,2,3*

1 Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, 2 School of Pharmacy, National Taiwan University, Taipei, Taiwan, 3 Departments of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan, 4 Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

These authors contributed equally to this work.
‡ L-JC and F-YH are first authors on this work.
* shuwenlin@ntu.edu.tw

Abstract

Objective
Existing data regarding the risk of hemorrhagic events associated with exposure to hypoprothrombinemia-inducing cephalosporins are limited by the small sample size. This population-based study aimed to examine the association between exposure to hypoprothrombinemia-inducing cephalosporins and hemorrhagic events using National Health Insurance Research Database in Taiwan.

Design
A nationwide nested case-control study.

Setting
National Health Insurance Research database.

Participants
We conducted a nested case-control study within a cohort of 6191 patients who received hypoprothrombinemia-inducing cephalosporins and other antibiotics for more than 48 hours. Multivariable conditional logistic regressions were used to calculate the adjusted odds ratio (aOR) and 95% confidence interval (CI) for hemorrhagic events associated with exposure to hypoprothrombinemia-inducing cephalosporins (overall, cumulative dose measured as defined daily dose (DDD), and individual cephalosporins).
Results
Within the cohort, we identified 704 patients with hemorrhagic events and 2816 matched controls. Use of hypoprothrombinemia-inducing cephalosporins was associated with increased risk of hemorrhagic events (aOR, 1.71; 95% CI, 1.42–2.06), which increased with higher cumulative doses (<3 DDDs, aOR 1.62; 3–5 DDDs, aOR 1.78; and >5 DDDs, aOR 1.89). The aOR for individual cephalosporin was 2.88 (95% CI, 2.08–4.00), 1.35 (1.09–1.67) and 4.57 (2.63–7.95) for cefmetazole, flomoxef, and cefoperazone, respectively. Other risk factors included use of anticoagulants (aOR 2.08 [95% CI, 1.64–2.63]), liver failure (aOR 1.69 [1.30–2.18]), poor nutritional status (aOR 1.41 [1.15–1.73]), and history of hemorrhagic events (aOR 2.57 [1.94–3.41]) 6 months prior to the index date.

Conclusions
Use of hypoprothrombinemia-inducing cephalosporins increases risk of hemorrhagic events. Close watch for hemorrhagic events is recommended when prescribing these cephalosporins, especially in patients who are at higher risk.

Key Points
This nested case-control study demonstrated that use of hypoprothrombinemia-inducing cephalosporins was associated with higher risk of hemorrhages in a cohort of 6191 patients. Cefoperazone, cefmetazole, flomoxef, anticoagulants, liver failure, poor nutritional status, and history of hemorrhages increased the risk.

Introduction
Cephalosporins are commonly prescribed and widely used to prevent or treat various infectious diseases. However, previous studies have suggested a potential correlation between certain cephalosporins and hemorrhagic tendency or events.[1–12] The potential mechanism regarding this risk is that cephalosporins may cause hypoprothrombinemia through inhibition of the growth of vitamin K–producing intestinal bacteria, such as Bacteroides spp., Enterobacteriaceae, and enterococci [13–15] or inhibition of vitamin K-epoxide reductase and vitamin K-dependent carboxylase.[16–19]

The cephalosporins that have been reported to increase risk of hemorrhagic tendency or events can be categorized into 4 groups based on different side chains attached to 3-position of the cephem nucleus. The first and the largest group of these cephalosporins is N-methylthiometrazole (NMTT)-side-chain-containing cephalosporins, which includes cefamandole, cefotetan, cefmatazole, moxalactam, and cefoperazone; each of them has been reported to induce hypoprothrombinemia or hemorrhage in case reports, interim analysis or post hoc analysis of randomized controlled trials.[1, 2, 5–12, 20]

Methylthiadiazolethiol (MTDT)-side-chain-containing cephalosporins such as cefazolin21 or n-hydroxyethyltetrazolethiol (HTT)-side-chain-containing cephalosporins such as flomoxef were found to result in inhibition of vitamin K-epoxide reductase in rats. In addition, cefoxitin, which is without any heterocyclic side chains attached to 3-position of cephem nucleus, has been reported to cause hypoprothrombinemia.[3]

However, most of the previous studies are limited by the small sample size and assessment of a single cephalosporin. In particular, it is uncertain that whether hypoprothrombinemia-
related bleeding has a dose–response relationship. The aim of this nested case-control study was therefore to investigate the association between exposure to hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events with the use of the National Health Insurance Research Database (NHIRD) in Taiwan.

Methods

Data source

The National Health Insurance (NHI) program, with approximately 23 million insured persons, covers over 99% of Taiwan’s population. The NHIRD is a nationwide research database which contains comprehensive records of demographics and claims data that record healthcare utilization, including outpatient visits, hospital admissions, prescription medications, and diagnoses, of beneficiaries of Taiwan’s NHI program. The data we used in this study were the subset of the NHIRD, the Longitudinal Health Insurance Database (LHID), which contained all inpatient and outpatient medical claims for approximately three million individuals (approximately 15% of all beneficiaries) randomly selected from the Registry for Beneficiaries of the NHIRD. The distribution of age, gender, and average insured payroll-related amount do not differ between the LHID and the NHIRD.[21]

Ethical statement

The protocol of our study was approved by the Research Ethics Committee of National Taiwan University Hospital (registration number, 201312061RINB). Because the identification numbers of all subjects in the NHRID were de-identified to protect individual privacy, informed consents were waived.

Study cohort

We identified a cohort composed of patients aged 20 years or greater who used selected intravenous antibiotics for more than 48 hours in the emergency room (ER) between 2000 and 2011. We excluded those who switched antibiotic regimen during ER stay. Patients who had hemorrhage-related diagnoses or who used vitamin K1, fresh frozen plasma, and coagulation factors II, VII, IX, and X in the ER were excluded to avoid carry-over effect of hemorrhagic events. The cohort entry date for each patient was defined as the date when a selected intravenous antibiotic was first prescribed in the ER.

Cases and Controls

From the study cohort, we identified patients hospitalized due to a hemorrhagic event subsequent to the use of antibiotics in the ER. A hemorrhagic event was defined as patients who hospitalized with a principal diagnosis codes of hemorrhage (International Classification of Diseases, 9th Revision, Clinical Modification codes (ICD-9-CM codes)) or who used vitamin K1, fresh frozen plasma, or coagulation factors II, VII, IX, and X during hospitalization. A detailed list of the ICD-9-CM codes for hemorrhage 24 is presented in Appendix 1. The date of hospital admission was defined as the index date. We randomly selected 4 controls for each case from the study cohort according to an incidence-density sampling strategy. Controls were matched to cases for age (+/- 5 years), sex, and the cohort entry date (+/- 1 year).

Exposure to Antibiotics

For each antibiotic a patient received at the ER visit, we further categorized them as hypoprothrombinemia-inducing cephalosporins and reference antibiotics. Hypoprothrombinemia-
inducing cephalosporins include cefmetazole, cefoxitin, cefotetan, flomoxef, moxalactam, cefamandole, and cefoperazone, which have been reported to cause hypoprothrombinemia or hemorrhage in previous studies. [1, 2, 5–12, 20]. Antibiotics with similar clinical indications but no previous reports of hypoprothrombinemia or hemorrhage, including amoxicillin-clavulanic acid, ampicillin-sulbactam, cefuroxime, ceftriaxone, and cefotaxime, were defined as reference antibiotics. Cumulative dose of hypoprothrombinemia-inducing cephalosporins and reference antibiotics was calculated based on defined daily dose (DDD) [22], and divided into three categories as less than 3 DDD, 3–5 DDDs, and more than 5 DDDs.

Indications for antibiotic use in the ER included septicemia [ICD-9-CM code: 038, 0419, and 7907], lower respiratory tract infections [480–483, 486, 487, 510, and 513], intra-abdominal infections [540–542, 56201, 56203, 56211, 56213, 566–567, 5695, 5720, 5721, and 5750], genitourinary tract infections [590, 5990, 601, and 614–616], skin and soft tissue infections [680–686], bone and joint infections [7110, and 730], and post-operation wound infections [9966, 9985, and 9993]. Using the outpatient and inpatient claims of the LHID, we identified the following comorbidities based on data within 6 months prior to the index date: overall comorbidity index calculated by Pharmacy-Based Disease Indicator (PBDI), chronic viral hepatitis, liver failure, renal disease, and malignancy. The PBDI, which was developed based on Chronic Disease Score (CDS), was an index consisting of 37 drug categories defined by Anatomical Therapeutic Chemical codes (ATC codes). It has also been validated in the NHIRD.[24]

Concomitant medications potentially associated with an altered hemorrhagic risk, including antiplatelet agents (ATC codes: B01AC and C04AD03), anticoagulants (B01AA–AB, B01AD–AE, and B01AX),[20] non-steroidal anti-inflammatory drugs (NSAIDs, M01AA–AC, M01AE, M01AG–AH, M01AX), drugs for chronic viral hepatitis (J05AB04, J05AF05, J05AF08, J05AF10–12, L03AB04–05, and L03AB09–11), drugs for liver failure (A06AD11, H01BA01, H01BA04, H01BA06, and H01CB01–02),[20, 25] drugs for renal disease (V03AE—and A11CC—),[3] and chemotherapeutic drugs (L01AA–AD, L01AG, L01AX, L01BA–BC, L01CA–CD, L01CX, L01DA–DC, L01XA–XE, L01XX–XY, L03AA, L03AC, and A04AA) [25] were also extracted from the NHIRD.

Statistical analysis
Multivariate conditional logistic regression models were used to estimate the association between the use of hypoprothrombinemia-inducing cephalosporins and risk of hemorrhagic events. All models were adjusted for indications for antibiotic use in the ER and potential risk factors of hemorrhagic events (comorbidities and concomitant medications). We also adjusted for other risk factors of hemorrhagic events, including surgery or other invasive procedures, coagulopathy or hemorrhagic events, and poor nutritional status (defined as use of total parenteral nutrition (TPN), megestrol, or tube feeding[3]) within 6 months prior to the index date. Coagulopathy were defined as a group of cytopenic and coagulopathic-related diseases identified by ICD-9-CM codes, including secondary to blood loss (ICD-9-CM code: 280.0), acute posthemorrhagic anemia (285.1), coagulation defects (286.xx), purpura and other hemorrhagic conditions (287.xx), unspecified diseases of blood and blood-forming organs (289.9) and abnormal coagulation profile (790.92). To minimize selection bias regarding indications for antibiotics between the cases and controls, the model was adjusted by the propensity score of indications for antibiotics. The propensity score was assigned based on the probability that an individual would receive a study antibiotic or not and estimated by a multivariable logistic regression model adjusting for underlying indications of antibiotics (i.e. septicemia, lower respiratory tract infections, intra-abdominal infections, genitourinary tract infections, skin and...
soft tissue infections, bone and joint infections, or post-operation wound infections) of a patient.

The fundamental model-fitting techniques for stepwise variable selection with entry criterion of 0.1 and staying criterion of 0.15 were conducted in our regression analyses, which means only variables having a significant univariate test (crude OR) at these specified levels are selected as candidates for the multivariate analysis.

We also conducted regression diagnostics of multicollinearity. Associations are presented as adjusted odds ratios (aORs) with confidence intervals stated at the 95% confidence level. All data in this study were analyzed using SAS® software, version 9.2 (SAS Institute, Cary, NC, USA).

Results

Among 6191 patients in the cohort, 704 case patients with hemorrhagic events and 2816 matched controls were identified (Fig 1). The mean age was 68 years and more than 60% (64.9%) were male (64.9%). In general, the case patients and controls shared a similar pattern with respect to indications for antibiotic use in the ER. However, case patients had significantly more frequent comorbidities than the controls, which was reflected by the PBDI (1.79 ± 1.29 versus 1.60 ± 1.29). Case patients were more likely to be diagnosed with coagulopathy (2.41% versus 0.46%) and hemorrhage (15.77% versus 5.82%), to undergo surgery or invasive procedures (48.44% versus 35.83%), and to have poor nutritional status (65.20% versus 51.31%) within 6 months prior to the index date. More case patients than controls used anticoagulants (20.60% versus 10.80%), NSAIDs (57.95% versus 54.72%), antiviral therapy for chronic viral hepatitis (1.85% versus 0.64%), medications for liver failure (17.47% versus 8.95%) and renal disease (7.39% versus 5.72%), and chemotherapy (10.23% versus 7.71%) within 6 months prior to the index date (Table 1).

More case patients used hypoprothrombinemia-inducing cephalosporins (38.49% versus 27.49%). Among all hypoprothrombinemia-inducing cephalosporins, flomoxef was the most frequently used (24.01% and 20.81% in case patients and controls, respectively). No patients in our study used cefotetan, moxalactam, and cefamandole in the ER. In contrast, more controls than case patients (72.51% versus 61.51%) used reference antibiotics. Among all reference antibiotics, ampicillin/sulbactam (27.27% and 30.54% in case patients and controls, respectively) was the most frequently used, followed by cefuroxime (12.22% and 16.23% in case patients and controls, respectively) (Table 2).

The conditional logistic regression model showed that the increased risk of hemorrhagic events was associated with exposure to hypoprothrombinemia-inducing cephalosporins (aOR 1.71; 95% CI, 1.42–2.06). In addition, higher hemorrhagic risks were found in patients who used anticoagulants (aOR 2.08; 95% CI, 1.64–2.63), had liver failure (aOR 1.69; 95% CI, 1.30–2.18), were in poor nutritional status (aOR 1.41 95% CI, 1.15–1.73), and had a history of hemorrhagic events (aOR 2.57; 95% CI, 1.94–3.41) (Table 3).

The association with hemorrhagic risks was stronger with higher cumulative exposure to hypoprothrombinemia-inducing cephalosporins, for which the aOR increased from 1.62 (95% CI, 1.28–2.05) for those with <3 DDDs, to 1.78 (95% CI, 1.35–2.34) for 3–5 DDDs, and to 1.89 (95% CI, 1.28–2.78) for those with >5 DDDs of hypoprothrombinemia-inducing cephalosporins (Table 4).

For individual hypoprothrombinemia-inducing cephalosporin, cefoperazone (aOR 4.57; 95% CI, 2.63–7.95), cefnetazole (aOR 2.88; 95% CI, 2.08–4.00) and flomoxef (aOR 1.35; 95% CI, 1.09–1.67) were all associated with increased risk of hemorrhagic event. No such association was found in users of cefoxitin (aOR 0.83; 95% CI, 0.33–2.08) (Table 5).
Discussion

In this population-based nested case-control study, we found an increased risk of hemorrhagic events associated with hypoprothrombinemia-inducing cephalosporins, which was demonstrated in a dose-response relationship with the highest risks seen in hypoprothrombinemia-inducing cephalosporins users with >5 DDDs in the ER. We also found that cefoperazone and
cefmetazole (NMTT-side-chain-containing cephalosporins) were associated with higher risks of hemorrhagic events. This phenomenon was consistent with the half-life of prothrombin (clotting factor II) and its major effect in the coagulation cascade.[17,18] The risk of hemorrhagic events was statistically significantly increased in patients who used anticoagulants as well as in patients with liver failure, poor nutritional status, and history of hemorrhagic events.

Our findings on the dose-response relationship of hypoprothrombinemia-inducing cephalosporins with increased hemorrhagic risks are in line with the only study so far that assessed the associations between hypoprothrombinemia and bleeding events with exposure to a higher cumulative dose of cefoperazone.[20] Furthermore, with the use of the Taiwanese NHIRD, we

| Table 1. Characteristics of cases and controls in the cohort. |
|---------------------------------------------------------------|
| Characteristics                                               | Cases          | Controls       | p-value |
|                                                             | (N = 704) | (N = 2816) |
| Gender                                                       | n (%)     | n (%)       |         |
| Male                                                         | 454 (64.49) | 1816 (64.49) | -       |
| Female                                                       | 250 (35.51) | 1000 (35.51) | -       |
| Age, mean [SD]                                               |          |             |         |
| 20–39 years                                                  | 67.64 [16.04] | 67.72 [16.60] | -       |
| 40–64 years                                                  | 44 (6.25) | 195 (6.92) | -       |
| 65 years and older                                           | 218 (30.97) | 872 (30.97) | -       |
| Indications for antibiotics                                 |           |             |         |
| Septicemia                                                   | 77 (10.94) | 307 (10.90) | 1.000   |
| Lower respiratory tract infections                           | 155 (22.02) | 807 (28.66) | <0.0001 |
| Intra-abdominal infections                                   | 34 (4.83) | 138 (4.90) | 0.951   |
| Genitourinary tract infections                               | 75 (10.65) | 333 (11.83) | 0.163   |
| Skin and soft tissue infections                              | 24 (3.41) | 195 (6.92) | <0.0001 |
| Bone and joint infections                                    | 2 (0.28) | 7 (0.25) | 1.000   |
| Post-operation wound infections                              | 0 (0.00) | 3 (0.11) | 1.000   |
| Prior medical conditions*                                    |           |             |         |
| PBDI                                                         | 1.79 (1.29) | 1.60 (1.29) | <0.0001 |
| Coagulopathy                                                 | 17 (2.41) | 13 (0.46) | <0.0001 |
| Hemorrhagic events                                           | 111 (15.77) | 164 (5.82) | <0.0001 |
| Cerebrovascular hemorrhage                                   | 7 (0.99) | 15 (0.53) | 0.066   |
| Gastrointestinal hemorrhage                                  | 67 (9.52) | 90 (3.20) | <0.0001 |
| Other types of hemorrhage                                    | 52 (7.39) | 80 (2.84) | <0.0001 |
| Surgery or invasive procedure                                | 341 (48.44) | 1009 (35.83) | <0.0001 |
| Poor nutritional status                                      | 459 (65.20) | 1445 (51.31) | <0.0001 |
| Prior medications*                                           |           |             |         |
| Anticoagulants                                               | 145 (20.60) | 304 (10.80) | <0.0001 |
| Antiplatelet agents                                          | 182 (25.85) | 757 (26.88) | 0.374   |
| NSAID                                                        | 408 (57.95) | 1541 (54.72) | 0.015   |
| Drugs for chronic viral hepatitis                            | 13 (1.85) | 18 (0.64) | <0.0001 |
| Drugs for liver failure                                      | 123 (17.47) | 252 (8.95) | <0.0001 |
| Drugs for renal disease                                      | 52 (7.39) | 161 (5.72) | 0.014   |
| Chemotherapeutic drugs                                       | 72 (10.23) | 217 (7.71) | <0.0001 |

*Prior medications and prior medical conditions were documented within six months prior to the index date.
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; PBDI, Pharmacy-Based Disease Indicator; SD, standard deviation

doi:10.1371/journal.pone.0158407.t001
are able to provide more comprehensive analysis of the risk of hemorrhagic events among an Asian population who receive hypoprothrombinemia-inducing cephalosporins for a variety of clinical indications.

Table 2. The comparison between the cases and the controls regarding use of study and reference antibiotics.

| Characteristics                                | Cases (N = 704) | Controls (N = 2816) | p-value |
|------------------------------------------------|-----------------|---------------------|---------|
| Hypoprothrombinemia-inducing cephalosporins    | 271 (38.49)     | 774 (27.49)         | <0.0001 |
| Cefmetazole                                    | 67 (9.52)       | 130 (4.62)          | <0.0001 |
| Cefoxitin                                      | 6 (0.85)        | 31 (1.10)           | 0.410   |
| Flomoxef                                       | 169 (24.01)     | 586 (20.81)         | 0.004   |
| Cefoperazone                                   | 29 (4.12)       | 27 (0.96)           | <0.0001 |
| Reference antibiotics                          | 433 (61.51)     | 2042 (72.51)        | <0.0001 |
| Amoxicillin/clavulanate                        | 111 (15.77)     | 608 (21.59)         | <0.0001 |
| Ampicillin/sulbactam                           | 192 (27.27)     | 860 (30.54)         | 0.007   |
| Cefuroxime                                     | 86 (12.22)      | 457 (16.23)         | <0.0001 |
| Cefotaxime                                     | 18 (2.56)       | 48 (1.70)           | 0.032   |
| Ceftriaxone                                    | 26 (3.69)       | 69 (2.45)           | 0.008   |

doi:10.1371/journal.pone.0158407.t002

Table 3. Risk factors of hemorrhagic events associated with use of study antibiotics.

| Hemorrhagic events                                      | Crude OR (95% CI) | p-value | Adjusted OR* (95% CI) | p-value |
|--------------------------------------------------------|-------------------|---------|-----------------------|---------|
| Use of hypoprothrombinemia-inducing cephalosporins      | 1.70 (1.42–2.03)  | <0.0001 | 1.71 (1.42–2.06)      | <0.0001 |
| Prior medication**                                      |                   |         |                       |         |
| Anticoagulants                                          | 2.16 (1.73–2.69)  | <0.0001 | 2.08 (1.64–2.63)      | <0.0001 |
| Drugs for liver failure                                 | 2.13 (1.69–2.69)  | <0.0001 | 1.69 (1.30–2.18)      | <0.0001 |
| Drugs for chronic viral hepatitis                       | 3.04 (1.46–6.36)  | 0.003   | 2.01 (0.91–4.42)      | 0.084   |
| Antiplatelet agents                                     | 0.94 (0.76–1.15)  | 0.563   |                       |         |
| NSAIDs                                                 | 1.15 (0.97–1.36)  | 0.116   |                       |         |
| Drugs for renal disease                                 | 1.31 (0.95–1.81)  | 0.100   |                       |         |
| Chemotherapeutic drugs                                  | 1.39 (1.04–1.85)  | 0.026   |                       |         |
| Prior medical events**                                  |                   |         |                       |         |
| Hemorrhagic events                                      | 3.01 (2.38–4.03)  | <0.0001 | 2.57 (1.94–3.41)      | <0.0001 |
| Poor nutritional status                                 | 1.79 (1.50–2.12)  | <0.0001 | 1.41 (1.15–1.73)      | 0.001   |
| Severity of illness calculated by PBDI                 | 1.12 (1.05–1.20)  | 0.006   | 0.92 (0.85–0.99)      | 0.038   |
| Surgery or invasive procedure                           | 1.69 (1.43–2.00)  | <0.0001 |                       |         |
| Coagulopathy                                            | 5.23 (2.54–10.77) | <0.0001 |                       |         |
| Age                                                     | 0.99 (0.96–1.03)  | 0.723   |                       |         |
| Indications for antibiotics calculated by propensity score# | 2.04 (1.30–3.20)  | 0.002   |                       |         |

*adjusted by use of anticoagulants, drugs for liver failure, and drugs for chronic viral hepatitis, occurrence of hemorrhagic events, and poor nutritional status within 6 months prior to the index date, and severity of illness calculated by PBDI within 6 months prior to the index date
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; CI, confidence interval; PBDI, Pharmacy-Based Disease Indicator
Prior medication and prior medical events**: within 6 months prior to the index date
# The propensity score was assigned based on the probability that an individual would receive a study antibiotic or not and estimated by a multivariable logistic regression model adjusting for underlying indications of antibiotics (i.e. septicemia, lower respiratory tract infections, intra-abdominal infections, genitourinary tract infections, skin and soft tissue infections, bone and joint infections, or post-operation wound infections) of a patient.

doi:10.1371/journal.pone.0158407.t003
Previous studies that investigated the hemorrhagic events among patients receiving hypoprothrombinemia-inducing cephalosporins are limited by small sample sizes. [1, 5, 20] By using the nationwide data, we had access to a larger cohort who used hypoprothrombinemia-inducing cephalosporins than existing studies, which allowed us to compare the risk of hemorrhagic events among different hypoprothrombinemia-inducing cephalosporins. The findings that cefoperazone, cefmetazole and flomoxef were at the highest risk among all antibiotics studied, and that the risks of cefoperazone and cefmetazole were much higher than that of flomoxef can be inferred from the previous study indicating that inhibition of vitamin K epoxide reductase caused by NMTT side chain was more intense than that by HTT side chain.[19]

In this study, we found that cefoperazone and cefmetazole (NMTT-side-chain-containing cephalosporins) were associated with 4.5 folds and 2.8 folds higher risk of bleeding events, respectively. Cefoperazone, the most commonly reported to cause hypoprothrombinemia in the previous studies, has been found to result in PT prolongation for more than 10 seconds in 2 case reports.[10, 11] In addition, 2 retrospective cohort studies also suggested that patients receiving cefoperazone were more likely to develop PT prolongation or hemorrhage than those receiving ceftizoxime/cefotaxime and ceftazidime.[4, 20]

In contrast, we did not found an increased hemorrhagic risk associated with another hypoprothrombinemia-inducing cephalosporin, cefoxitin. This is inconsistent with a retrospective study done by Brown et al, in which they reported that cefoxitin users were more likely to experience hemorrhagic events than users of cezafolin, chloramphenicol, erythromycin, nafcillin or oxacillin, and vancomycin.[3] Small case numbers of patients with exposure to cefoxitin in our study could be a potential explanation as only 6 case patients and 31 controls received cefoxitin.

Our study identified several important risk factors of hemorrhagic event among our study subjects. In addition to common risk factors of bleeding events such as use of anticoagulants or

| Table 4. Dose-dependent effect regarding association between use of study antibiotics and hemorrhagic tendency/events. |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Reference antibiotics                              | N (%)           | Crude OR (95% CI) | p-value | Adjusted OR *(95% CI) | p-value |
| Cumulative dose of study antibiotics               | Reference       | Reference       | Reference       | Reference       | Reference       |
| < 3 DDD                                           | 2475            | 1.58 (1.26–1.97) | < 0.0001       | 1.62 (1.28–2.05) | < 0.0001       |
| ≥ 3 DDD, < 5 DDD                                  | 558             | 1.80 (1.38–2.35) | < 0.0001       | 1.78 (1.35–2.34) | < 0.0001       |
| ≥ 5 DDD                                          | 336             | 1.94 (1.34–2.82) | 0.0005         | 1.89 (1.28–2.78) | 0.0013         |

*adjusted by use of anticoagulants, drugs for liver failure, and drugs for chronic viral hepatitis, occurrence of hemorrhagic events, and poor nutritional status within 6 months prior to the index date, and severity of illness calculated by PBID

Abbreviations: DDD, defined daily dose; ER, emergency room; OR, odds ratio; CI = confidence interval

doi:10.1371/journal.pone.0158407.t004

| Table 5. Risk of hypoprothrombinemia or hemorrhagic events associated with use of individual study antibiotics. |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Reference antibiotics                              | Cases (N = 704) | Controls (N = 2816) | Crude OR (95% CI) | p-value | Adjusted OR *(95% CI) | p-value |
| Cefmetazole                                      | 433             | 2042            | Reference       | Reference       | Reference       | Reference       |
| Flomoxef                                         | 67              | 130             | 2.46 (1.80–3.36) | <0.0001       | 2.88 (2.08–4.00) | <0.0001       |
| Cefoxitin                                        | 169             | 586             | 1.39 (1.13–1.71) | 0.002         | 1.35 (1.09–1.67) | 0.006         |
| Cefoperazone                                     | 6               | 31              | 0.85 (0.34–2.11) | 0.73          | 0.83 (0.33–2.08) | 0.69          |
| Cefoperazone                                     | 29              | 27              | 4.93 (2.89–8.41) | <0.0001       | 4.57 (2.63–7.95) | <0.0001       |

*adjusted by use of anticoagulants, drugs for liver failure, and drugs for chronic viral hepatitis, occurrence of hemorrhagic events, and poor nutritional status within 6 months prior to the index date, and severity of illness calculated by PBID

doi:10.1371/journal.pone.0158407.t005
history of hemorrhagic event, we found that poor nutritional status was associated with a 40% increase of risk of hemorrhagic event (aOR 1.41; 95% CI, 1.15–1.73). These findings gave support to a case report that demonstrated a patient with poor nutritional status and end-stage renal disease who was noted to have elevated international normalized ratio (INR) level after receiving post-surgery cefmetazole.[2]

Some limitations of this study should be acknowledged. First, the patients who were hospitalized without receiving care at the ER were not included in this analysis. Second, we were unable to include variables not routinely captured in claims database, such as laboratory data. We thus were unable to identify INR prolongation as our study endpoint or identify hypoalbuminemia as one of the covariates. Instead, we retrieved use of vitamin K, FFP, or coagulation factors II, VII, IX, and X as surrogates for INR prolongation, and use of TPN, megestrol, and tube feeding for poor nutritional status. We also may not fully capture platelet dysfunction for our study cohort. However, we have retrieved our data and found none of our cases with bleeding and controls had a diagnosis of thrombocytopenia nor do they ever received platelet transfusion. In addition, covariates which can affect a subject’s platelet number or function were considered in our statistical models. We believe we have done our best to control the potential differences in covariates between our cases and control.

Third, dose adjustment of antibiotics due to renal impairment or antibiotic regimens for diverse infectious diseases with severity that could vary widely may not be well captured in the NHIRD. However, we used DDDs to calculate cumulative doses of antibiotics, which is commonly used for measurement of exposure to different medications in studies using claims data. Fourth, we did not consider cefazolin in our study, which was mainly due to the different antimicrobial spectrums between cefazolin and our study antibiotics (cefmetazole, cefoxitin, cefotetan, flomoxef, moxalactam, cefamandole, and cefoperazone). Including cefazolin as one of our study antibiotics may result in diverse discrepancies, in terms of indications and clinical characteristics, among our study subjects. In addition, existing evidence regarding cefazolin-associated hypoprothrombinemia is very limited as this potential association was only reported in one case report [4]. Nevertheless, further studies regarding cefazolin-associated hypoprothrombinemia are warranted.

In conclusion, we found an increased risk of hemorrhagic events associated with exposure to hypoprothrombinemia-inducing cephalosporins, especially NMTT-side-chain-containing cephalosporins (cefoperazone and cefmetazole). Close monitoring of INR levels is recommended mainly in patients who are on anticoagulants, in poor nutritional status, or with underlying liver failure or a history of hemorrhagic events.

Author Contributions
Conceived and designed the experiments: SWL FYH LJS CCH FLLW WT LJC. Performed the experiments: SWL FYH LJC. Analyzed the data: LJC. Contributed reagents/materials/analysis tools: FYH. Wrote the paper: SWL FYH LJS CCH FLLW WT LJC.

References
1. Bertino JS Jr., Kozak AJ, Reese RE, Chiarello LA. Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital. Arch Intern Med. 1986; 146(6):1125–8. PMID: 3718099
2. Breen GA, St Peter WL. Hypoprothrombinemia associated with cefmetazole. Ann Pharmacother. 1997; 31(2):180–4. PMID: 9034420
3. Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M. Enhanced bleeding with cefoxitin or moxalactam: Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986; 146(11):2159–64. PMID: 3778044
4. Chung AH, Watson K. Cefazolin-induced hypoprothrombinemia. Am J Health Syst Pharm. 2008; 65(9):823–6. doi: 10.2146/ajhp070243 PMID: 18436729
5. Joshi M, Fitzpatrick BJ, Warren JW, Caplan ES, Tenney JH. A randomized controlled trial of moxalactam versus clindamycin/tobramycin in the treatment of mixed anaerobic/aerobic infections. Am Surg. 1986; 52(9):467–71. PMID: 3530075
6. Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA. Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan. Arch Surg. 1991; 126(4):524–5. PMID: 1901205
7. Mueller RJ, Green D, Phair JP. Hypoprothrombinemia associated with cefoperazone therapy. South Med J. 1987; 80(11):1360–2. PMID: 3686136
8. Nichols RL, Wikler MA, McDevitt JT, Lentnek AL, Hosutt JA. Coagulopathy associated with extended-spectrum cephalosporins in patients with serious infections. Antimicrob Agents Chemother. 1987; 31(2):281–5. PMID: 3471181
9. Pakter RL, Russell TR, Mielke C, West D. Coagulopathy associated with the use of moxalactam. JAMA. 1982; 248(9):1100–5. PMID: 6213792
10. Parker S, Baxter J, Beam TJR. Cefoperazone-induced coagulopathy. The Lancet. 323(8384):1016.
11. Wong RS, Cheng G, Chan NP, Wong WS, Ng MH. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol. 2006; 81(1):78.
12. Wurtz RM, Sande MA. Cefotetan and coagulopathy. J Infect Dis. 1989; 160(3):555–6.
13. Bang NU, Tessler SS, Heidenreich RO, Marks CA, Mattler LE. Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis. 1982; 4 Suppl:S546–54. PMID: 6218565
14. Cooke G, Behan J, Costello M. Newly identified vitamin K-producing bacteria isolated from the neonatal faecal flora. Microbial Ecology in Health and Disease. 2006; 18(3–4):133–8.
15. Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev. 1997; 6 Suppl 1:S43–5. PMID: 9167138
16. Bechtold H, Andrassys K, Jahnchen E, Koderisch J, Koderisch H, Willeman LS, et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost. 1984; 51(3):358–61. PMID: 6548584
17. Lipsky JJ. Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics. Proc Natl Acad Sci U S A. 1984; 81(9):2893–7. PMID: 6585834
18. Shearer MJ, Bechtold H, Andrassys K, Koderisch J, McCarthy PT, Trenk D, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol. 1988; 28(1):88–95. PMID: 3350995
19. Uchida K, Matsubara T. Effect of flomoxef on blood coagulation and alcohol metabolism. Infection. 1991; 19 Suppl 5:S284–95. PMID: 1783445
20. Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 1999; 8(2):81–94. PMID: 15073933
21. National Health Insurance Research Database, Taiwan. [cited 2013 Dec. 31]; Available from: http://nhird.nhri.org.tw/ [Internet].
22. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2013. Oslo 2012. [Internet].
23. Wang JL, Chang CH, Lin JW, Wu LC, Chuang LM, Lai MS. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int J Cancer. 2014; 135(4):956–67. doi: 10.1002/ijc.28738 PMID: 24470385
24. Dong YH, Chang CH, Shau WY, Kuo RN, Lai MS, Chan KA. Development and validation of a pharmacy-based comorbidity measure in a population-based automated health care database. Pharmacotherapy. 2013; 33(2):126–36. doi: 10.1002/phar.1176 PMID: 23386595
25. Goss TF, Walawander CA, Grasela TH Jr., Meisel S, Katona B, Jaynes K. Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patients. Pharmacotherapy. 1992; 12(4):283–91.